AC Immune (ACIU) Cash from Operations (2015 - 2025)

AC Immune (ACIU) has 11 years of Cash from Operations data on file, last reported at 20932070.62 in Q4 2025.

• On a quarterly basis, Cash from Operations fell 409.02% year-over-year to 20932070.62 in Q4 2025; TTM through Dec 2025 was 85385299.71, a 217.97% decrease from a year earlier, with the FY2025 full-year figure at 85598939.26, down 213.89% from the prior year.
• Cash from Operations for Q4 2025 stood at 20932070.62, up from 23352045.73 in the prior quarter.
• Over the last five years, Cash from Operations for ACIU reached as high as 80752780.98 in Q2 2024 and fell as low as 24913255.16 in Q1 2022.
• Historically, Cash from Operations has averaged 11473506.61 across 5 years, with a median of 18098045.55 in 2022.
• Across the five-year window, Cash from Operations surged 611.76% in 2024 and sank 1935.27% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 19702149.61 in 2021, then grew by 8.48% to 18031478.64 in 2022, then decreased by 2.35% to 18454792.73 in 2023, then soared by 136.7% to 6773790.65 in 2024, then slumped by 409.02% to 20932070.62 in 2025.
• Per Business Quant data, the three most recent Cash from Operations figures were 20932070.62 in Q4 2025, 23352045.73 in Q3 2025, and 19570237.49 in Q2 2025.